

To the editors and reviewers

We thank you for your feedback. We have made changes to the manuscript. Please find below a point-by-point response to queries raised.

Kind regards

Reviewer Number 1:

1. The title of the study can be modified to a single center experience from Jordan instead of including the hospital

We have changed the title to **Manifestations of COVID-19 infection in children having malignancy: A single centre experience in Jordan** as you recommend.

2. Was there a difference amongst disease severity amongst different malignancy groups, statistical analysis can be utilized to address this

We have clarified and added the disease severity amongst each malignancy group in the results and discussion sections as we found that COVID-19 infection is more severe in patients with hematological malignancies in comparison to patients with solid tumors who were only asymptomatic or had mild symptoms of COVID-19.

3. Limitations of the study should be added

Limitations of the study were added at the end of the discussion section. Limitations of this study included the small number of the cases as this study includes just one institution experience in a short period of time. Another limitation of this study was the short follow up period of these patients which prevented us from detecting the possible long term complications.

Reviewer Number 2:

1. Great deal of English proof read is needed

Proof reading and editing were done for the manuscript for the second time via www.proofreadingervices.com , certificate is attached.

2. May I suggest to make tabular presentation of the available literature

Actually we tried to compare our results as much as we can with the international similar articles, and we mention that separately in the discussion section, so collecting these results in a table will lead to a huge table, so we prefer to keep the comparison in the discussion section in a comprehensive way.

3. Please do mention if any particle malignancy has mentionable increase or decrease

We mention the answer of your question in the discussion section as we did not notice any increase in the incidence of any malignancy groups during the COVID-19 era which indicates that the virus is not an oncogenic virus at least in the short term.

4. Any potential limitations

Limitations of the study were added at the end of the discussion section.

5. Future directions to the readers.

Future directions to the readers were added at the end of the conclusion section. This include the following: chemotherapy has to be continued for patients with cancer during the era of COVID-19 providing that the WHO recommendations are strictly applied and providing that your patients are not severely suppressed and tested negative for COVID-19. However, prevention of severe neutropenia by giving G-CSF as a bone marrow rescue is mandatory to prevent the moderate to severe symptoms of COVID-19 in malignancy patients.